Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514–23. https://doi.org/10.1056/NEJMoa1310799.

Article  PubMed  CAS  Google Scholar 

CDC [Internet]. 2024. National Diabetes Statistics Report. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html.

Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82. https://doi.org/10.1016/S0140-6736(13)60591-7.

Article  PubMed  Google Scholar 

Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diab. 2009;10:3–12. https://doi.org/10.1111/j.1399-5448.2009.00568.x.

Article  Google Scholar 

Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019;128:94–105. https://doi.org/10.1016/j.neuint.2019.04.010.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ahrén B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays. 1998;20:642–51.

Article  PubMed  Google Scholar 

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740–56. https://doi.org/10.1016/j.cmet.2018.03.001.

Article  PubMed  CAS  Google Scholar 

Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015;95:513–48. https://doi.org/10.1152/physrev.00013.2014.

Article  PubMed  CAS  Google Scholar 

Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol. 2010;92:442–62. https://doi.org/10.1016/j.pneurobio.2010.07.003.

Article  PubMed  CAS  Google Scholar 

Marzook A, Tomas A, Jones B. The interplay of glucagon-like peptide-1 receptor trafficking and signalling in pancreatic beta cells. Front Endocrinol. 2021;12:678055. https://doi.org/10.3389/fendo.2021.678055.

Article  Google Scholar 

Ismail R, Csóka I. Novel strategies in the oral delivery of antidiabetic peptide drugs-Insulin, GLP 1 and its analogs. Eur J Pharm Biopharm. 2017;115:257–67. https://doi.org/10.1016/j.ejpb.2017.03.015.

Article  PubMed  CAS  Google Scholar 

Manandhar B, Ahn JM. Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications. J Med Chem. 2015;58:1020–37. https://doi.org/10.1021/jm500810s.

Article  PubMed  CAS  Google Scholar 

Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharm Rev. 2003;55:167–94. https://doi.org/10.1124/pr.55.1.6.

Article  PubMed  CAS  Google Scholar 

Seewoodhary J, Davies J. Novel GLP-1 mimetics in diabetes: lixisenatide and albiglutide. Future Prescr. 2011;12:20–2. https://doi.org/10.1002/fps.79.

Article  Google Scholar 

Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid. 2011;67–79. https://doi.org/10.2147/CE.S15525.

Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1 agonists: current advancements & challenges. Biomed Pharmacother. 2018;108:952–62. https://doi.org/10.1016/j.biopha.2018.08.088.

Article  PubMed  CAS  Google Scholar 

Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med. 1999;16:332–8. https://doi.org/10.1046/j.1464-5491.1999.00081.x.

Article  PubMed  CAS  Google Scholar 

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51:424–9. https://doi.org/10.2337/diabetes.51.2.424.

Article  PubMed  CAS  Google Scholar 

Knudsen LB. Inventing liraglutide, a glucagon-like peptide-1 analogue, for the treatment of diabetes and obesity. ACS Pharm Transl Sci. 2019;2:468–84. https://doi.org/10.1021/acsptsci.9b00048.

Article  CAS  Google Scholar 

Gault VA, Flatt PR, Harriott P, Mooney MH, Bailey CJ, O’Harte FPM. Improved biological activity of Gly^ 2-and Ser^ 2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J Endocrinol. 2003;176:133–42. https://doi.org/10.1677/joe.0.1760133.

Article  PubMed  CAS  Google Scholar 

Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diab Ther. 2021;12:143–57. https://doi.org/10.1007/s13300-020-00981-0.

Article  CAS  Google Scholar 

Mentis N, Vardarli I, Köthe LD, Holst JJ, Deacon CF, Theodorakis M, et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 2011;60:1270–6. https://doi.org/10.2337/db10-1332.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pratley RE. GIP: an inconsequential incretin or not?. Diab Care Am Diab Assoc. 2010;33:1691–2. https://doi.org/10.2337/dc10-0704.

Article  Google Scholar 

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. https://doi.org/10.1016/j.molmet.2018.09.009.

Article  PubMed  PubMed Central  CAS  Google Scholar 

WHO [Internet]. 2024 [cited 2024 Dec 30]. Disease Outbreak News (DONs). Available from: https://www.who.int/emergencies/disease-outbreak-news

Naver SV, Jimenez-Solem E, Christensen M, Andersen JT, Knop FK. Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. 2014; https://doi.org/10.4155/cli.14.65.

Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:234 https://doi.org/10.1038/s41392-024-01931-z.

Article  PubMed  PubMed Central  Google Scholar 

Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, et al. Once-weekly efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to liraglutide. Diab Care. 2019;42:1733–41. https://doi.org/10.2337/dc18-2648.

Article  CAS  Google Scholar 

Reid J, Rana K, Segel SA, Sheikh-Ali M, Choksi RR, Goldfaden RF. Efpeglenatide. Glucagon-like peptide 1 (GLP-1) receptor agonist, treatment for type 2 diabetes. Drugs Future. 2019;44. https://doi.org/10.1358/dof.2019.44.6.2927591.

International Pharmaceutical Industry [Internet]. Nanoformulation for enhanced drug delivery and better patient compliance. Available from: https://international-pharma.com/wp-content/uploads/2023/09/Nanoformulation-for-Enhanced-Drug-Delivery-and-Better-Patient-Compliance.pdf.

Jeevanandam J, San Chan Y, Danquah MK. Nano-formulations of drugs: recent developments, impact and challenges. Biochimie. 2016;128:99–112. https://doi.org/10.1016/j.biochi.2016.07.008.

Article  PubMed  CAS  Google Scholar 

Tiwary P, Oswal K, Varghese R, Anchan H, Gupta P. Solid lipid nanoparticles in the diagnosis and treatment of prostate cancer: a comprehensive review of two decades of advancements. Chem Phys Lipids. 2025;105510. https://doi.org/10.1016/j.chemphyslip.2025.105510.

Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Controlled Release. 2005;102:313–32. https://doi.org/10.1016/j.jconrel.2004.10.015.

Article  CAS  Google Scholar 

Bao Z, Kim J, Kwok C, Le Devedec F, Allen C. A dataset on formulation parameters and characteristics of drug-loaded PLGA microparticles. Sci Data. 2025;12:364. https://doi.org/10.1038/s41597-025-04621-9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

da Silva RYP, de Menezes DLB, Oliveira V, da S, Converti A, de Lima ÁAN. Microparticles in the development and improvement of pharmaceutical formulations: an analysis of in vitro and in vivo studies. Int J Mol Sci. 2023;24:5441 https://doi.org/10.3390/ijms24065441.